This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
by Riya Anand
SNDL's (SNDL) first-quarter performance is expected to benefit from reduced cost expenses and expansion into the liquor retail segment.
McKesson (MCK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fourth-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Should You Buy Hims & Hers Health (HIMS) Ahead of Q1 Earnings?
by Urmimala Biswas
Hims & Hers Health's (HIMS) first-quarter earnings are expected to have benefited from its strategy of placing its solutions at attractive price points.
Will Rate Hikes Aid Hartford Financial's (HIG) Q1 Earnings?
by Zubia Masood
Hartford Financial's (HIG) Q1 results are likely to benefit from new business growth and expanding margins in the Commercial Lines unit, partly offset by the poor performance of the auto business.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Strength in the Surgical and Vision Care businesses bodes well for Alcon (ALC).
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights Booking Holdings, Mitsubishi UFJ Financial, Micron Technology, American Electric Power and Alcon
by Zacks Equity Research
Booking Holdings, Mitsubishi UFJ Financial, Micron Technology, American Electric Power and Alcon are part of the Zacks Analyst Blog.
Top Analyst Reports for Booking Holdings, Mitsubishi UFJ & Micron Technology
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Booking Holdings Inc. (BKNG), Mitsubishi UFJ Financial Group, Inc. (MUFG) and Micron Technology, Inc. (MU).
Alcon's (ALC) New Launch Strengthens IOL Innovation Leadership
by Zacks Equity Research
Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.
Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone
by Zacks Equity Research
Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Alcon (ALC) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Alcon (ALC) delivers impressive performance across its franchises in the fourth quarter of 2023.
Alcon (ALC) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Alcon (ALC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario
by Zacks Equity Research
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
Wall Street's Insights Into Key Metrics Ahead of Alcon (ALC) Q4 Earnings
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Alcon (ALC), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Alcon (ALC) Business Hurt by Macroeconomic Woes, Competition
by Zacks Equity Research
In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.
ALC or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALC vs. IDXX: Which Stock Is the Better Value Option?
Company News for Nov 16, 2023
by Zacks Equity Research
Companies In The News Are: ALC, XPEV, OLK, AAP.
Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase
by Zacks Equity Research
Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.
Alcon (ALC) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Here's Why Investors Should Buy Alcon (ALC) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Alcon (ALC), backed by a competitive product portfolio and strong commercial execution.
Is Alcon (ALC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alcon (ALC) and Alpine Immune Sciences, Inc. (ALPN) have performed compared to their sector so far this year.
Alcon (ALC) Unveils New Progress in Presbyopia Correcting IOLs
by Zacks Equity Research
Alcon's (ALC) Clareon Vivity IOL highlights proven results and high levels of patient satisfaction. It will offer a similar halo profile compared with a monofocal IOL.
Zacks Industry Outlook Highlights Alcon, STERIS and Inari Medical
by Zacks Equity Research
Alcon, STERIS and Inari Medical are part of the Zacks Industry Outlook article.
3 Medical Instruments Stocks Countering Industry-Wide Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is being affected by ongoing inflation and a tightening monetary policy. However, the rising demand for digital health offers some respite. ALC, STE and NARI are poised to brave the challenges.